MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomas
Contributeurs/tricesFuster-Garcia, Elies; Lorente Estellés, David; Álvarez-Torres, María Del Mar; Juan-Albarracín, Javier; Chelebian, Eduard; Rovira, Alex; Acosta, Cristina Auger; Pineda, Jose; Oleaga, Laura; Mollá-Olmos, Enrique; Filice, Silvano; Due-Tønnessen, Paulina; Meling, Torstein; Emblem, Kyrre E; García-Gómez, Juan M
Publié dansEuropean Radiology, vol. 31, no. 3, p. 1738-1747
Date de publication2021
Résumé
Mots-clés
- Antineoplastic Agents
- Alkylating/therapeutic use
- Brain Neoplasms/diagnostic imaging/drug therapy/genetics
- DNA Methylation
- DNA Modification Methylases/genetics
- DNA Repair Enzymes/genetics
- Glioblastoma/diagnostic imaging/genetics
- Humans
- Prognosis
- Promoter Regions
- Genetic
- Temozolomide/therapeutic use
- Tumor Suppressor Proteins/genetics
Structure d'affiliation
Groupe de recherche
Financement
- European Commission - 727560, 825750, 758657
- European Commission - 844646
Citation (format ISO)
FUSTER-GARCIA, Elies et al. MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomas. In: European Radiology, 2021, vol. 31, n° 3, p. 1738–1747. doi: 10.1007/s00330-020-07297-4
Fichiers principaux (1)
Article (Published version)
Identifiants
- PID : unige:158179
- DOI : 10.1007/s00330-020-07297-4
- PMID : 33001310
URL commercialhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880975/
ISSN du journal0938-7994
